Please select the option that best describes you:

Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?  

Comorbidities: morbid obesity, diabetes, hypertension



Answer from: Medical Oncologist at Academic Institution